Similar articles

• Is olanzapine a brain-sparing medication?

  Joober R, Schmitz N, Malla A, Sengupta S, Karma S. Joober R, et al. Arch Gen Psychiatry. 2006 Nov;63(11):1292. doi: 10.1001/archpsyc.63.11.1292. Arch Gen Psychiatry. 2006. PMID: 17088510 No abstract available.
• Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.

  Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Ascher-Svanum H, et al. BMC Psychiatry. 2005 Jan 13;5:3. doi: 10.1186/1471-244X-5-3. BMC Psychiatry. 2005. PMID: 15649317 Free PMC article. Clinical Trial.
• Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.

  Yamamoto K, Fukuda M, Nogawa A, Takahashi E, Miyaoka H. Yamamoto K, et al. J Clin Psychiatry. 2007 May;68(5):802. doi: 10.4088/jcp.v68n0522e. J Clin Psychiatry. 2007. PMID: 17503998 No abstract available.
• Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.

  Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, de Haan L, Chawla B. Karagianis J, et al. Hum Psychopharmacol. 2008 Jun;23(4):275-81. doi: 10.1002/hup.933. Hum Psychopharmacol. 2008. PMID: 18338426 Review.
• Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.

  eder-Ischia U, Ebenbichler C, Fleischhacker WW. eder-Ischia U, et al. Essent Psychopharmacol. 2005;6(2):112-7. Essent Psychopharmacol. 2005. PMID: 15765795 Review.